Axel Lischewski

This inventor holds 14 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 7 EPO patents, primarily in Veterinary Vaccines. Top assignees: Boehringer Ingelheim Vetmedica Gmbh, Other. Active years: 2011-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Axel Lischewski. Retrieved from https://idiyas.com/inventor/axel-lischewski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 6.3

ph-index = 8

Forward Citations = 171(Granted Patents)

Location History:

St. Joseph, MO (US) (2011)
Saint Joseph, MO (US) (2011 - 2013)
Ingelheim am Rhein, DE (2014 - 2016)
Ockenhiem, DE (2018)
Ingelheim am Rheim, DE (2018)
Ockenheim, DE (2015 - 2020)

Company Filing History:

13 out of 317

Boehringer Ingelheim Vetmedica Gmbh

patents

1 out of 834,601

Other

patents

Years Active: 2011-2020

Loading Chart...

Areas of Expertise:

PCV2 Antigen

PRDC Treatment

Schmallenberg Virus

Vaccine Production

Sub-Clinical PCVD

Prophylaxis

Veterinary Medicine

Animal Health

Vaccine Methods

Infectious Diseases

Pigs

Viral Infections

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10780156 - Treatment of pigs with PCV2 antigen (2020-09-22),

2. 10010604 - Treatment of PRDC in pigs (2018-07-03),

3. 10010603 - Treatment of pigs with PCV2 antigen (2018-07-03),

4. 9943587 - Prevention and treatment of sub-clinical PCVD (2018-04-17),

5. 9872897 - Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof (2018-01-23),

6. 9555092 - Prevention and treatment of sub-clinical PCVD (2017-01-31),

7. 9522182 - Prophylaxis and treatment of PRDC (2016-12-20),

8. 9517260 - Treatment of pigs with PCV2 antigen (2016-12-13),

9. 9370562 - Schmallenberg virus (SBV) vaccine, methods of production, and uses thereof (2016-06-21),

10. 9132187 - Prevention and treatment of sub-clinical PCVD (2015-09-15),

11. 8865183 - Treatment of pigs with PCV2 antigent (2014-10-21),

12. 8496940 - Prevention and treatment of sub-clinical PCVD (2013-07-30),

13. 7943298 - Prevention and treatment of sub-clinical PCVD (2011-05-17),

14. 7914992 - Treatment of PRDC in pigs (2011-03-29),

Title: Axel Lischewski: Innovator in Veterinary Medicine

Introduction

Axel Lischewski is a notable inventor based in Ockenheim, Germany. He has made significant contributions to the field of veterinary medicine, particularly in the treatment of viral infections in pigs. With a total of 14 patents to his name, Lischewski's work has had a profound impact on animal health.

Latest Patents

One of Lischewski's latest patents focuses on the treatment of pigs with PCV2 antigen. This invention relates to a method for the treatment or prophylaxis of a PCV2 infection, aimed at reducing clinical symptoms associated with the infection. The method is particularly effective for animals that have anti-PCV2 antibodies or for young piglets aged 1 to 22 days. The administration of an effective amount of PCV2 antigen is crucial for those animals in need of such treatment.

Career Highlights

Throughout his career, Axel Lischewski has worked with prominent companies in the veterinary field, including Boehringer Ingelheim Vetmedica GmbH. His expertise and innovative approaches have positioned him as a key figure in veterinary research and development.

Collaborations

Lischewski has collaborated with several professionals in his field, including Vicky Fachinger and Knut Elbers. These collaborations have further enhanced his research and contributed to the advancement of veterinary medicine.

Conclusion

Axel Lischewski's contributions to veterinary medicine through his innovative patents and collaborations highlight his dedication to improving animal health. His work continues to influence the industry and offers promising solutions for the treatment of viral infections in pigs.

Profile summary based on public USPTO records.